HeartFlow, Inc. is launching its next generation of its FFRct Analysis platform, which offers major advancements in the process and algorithms it uses to calculate FFRct values.
These technology advancements resulted in the second FDA clearance for HeartFlow’s technology. The company plans to introduce the platform to new and existing customers in the coming weeks.
Major enhancements include:
- Advanced algorithms and streamlined case processing, which will provide the HeartFlow Analysis results to clinicians more quickly
- Cloud-based infrastructure utilizing Amazon Web Services (AWS), to ensure that delivery of the HeartFlow service is more secure, robust and scalable
- Increased security measures to address the needs of healthcare institutions worldwide
The HeartFlow Analysis is a non-invasive technology providing insight into both the extent of coronary artery disease and the impact that disease has on blood flow to the heart, enabling clinicians to select an appropriate treatment, according to the company.
The technology, which first received de novo clearance from the FDA in 2014, is also available in Canada, Europe and Japan, and has been used to guide the treatment of thousands of patients globally.
Charles A. Taylor, PhD, co-founder of HeartFlow, said the cloud-based platform utilizes data received from clinicians globally and, as the number of patients grows, the data set and analysis continues to improve through the application of deep learning technology.
Deep learning involves integrating multiple layers of nonlinear algorithms to help identify patterns and improve understanding of the information. By applying deep learning to large amounts of image data, the technology has the potential to improve the performance with future software releases to help physicians better manage patients with coronary artery disease, according to the company.
